Current management of locoregional and oligometastatic melanoma is typically with surgery; however, some patients are unable to undergo resection due to location/size of their tumors and/or the anticipated morbidity of the surgery. While there are currently no established guidelines for neoadjuvant therapy in melanoma, neoadjuvant BRAF-targeted therapy may make resection more feasible. A retrospective analysis was conducted of 23 patients with BRAFV600-mutant, stage III/IV melanoma treated with BRAF-targeted therapy prior to surgery, with no adjuvant treatment. Surgical specimens, preoperative imaging, and clinical outcomes were evaluated. Results: Ten of 23 patients (44%) attained a pathologic complete response (pCR), with no correlation between RECIST response based on preoperative imaging and pathologic response. After a median of 43-month follow-up, only 1 patient (10%) with a pCR recurred, while 8 of 13 (62%) patients without a pCR recurred. Patients with a pCR had significantly improved relapse-free (RFS) and overall survival (OS) compared to patients with residual tumor. Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS.
Current management of locoregional and oligometastatic melanoma is typically with surgery; however, some patients are unable to undergo resection due to location/size of their tumors and/or the anticipated morbidity of the surgery. While there are currently no established guidelines for neoadjuvant therapy in melanoma, neoadjuvant BRAF-targeted therapy may make resection more feasible. A retrospective analysis was conducted of 23 patients with BRAFV600-mutant, stage III/IV melanoma treated with BRAF-targeted therapy prior to surgery, with no adjuvant treatment. Surgical specimens, preoperative imaging, and clinical outcomes were evaluated. Results: Ten of 23 patients (44%) attained a pathologic complete response (pCR), with no correlation between RECIST response based on preoperative imaging and pathologic response. After a median of 43-month follow-up, only 1 patient (10%) with a pCR recurred, while 8 of 13 (62%) patients without a pCR recurred. Patients with a pCR had significantly improved relapse-free (RFS) and overall survival (OS) compared to patients with residual tumor. Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS.
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Karlijn Koers; Anne Brecht Francken; John B A G Haanen; Leonie A E Woerdeman; Jos A van der Hage Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Marco Rastrelli; Jacopo Pigozzo; Antonio di Maggio; Anna L Tosi; Vanna Chiarion Sileni; Carlo R Rossi Journal: Melanoma Res Date: 2014-08 Impact factor: 3.599
Authors: M T Tetzlaff; J L Messina; J E Stein; X Xu; R N Amaria; C U Blank; B A van de Wiel; P M Ferguson; R V Rawson; M I Ross; A J Spillane; J E Gershenwald; R P M Saw; A C J van Akkooi; W J van Houdt; T C Mitchell; A M Menzies; G V Long; J A Wargo; M A Davies; V G Prieto; J M Taube; R A Scolyer Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Rodabe N Amaria; Peter A Prieto; Michael T Tetzlaff; Alexandre Reuben; Miles C Andrews; Merrick I Ross; Isabella C Glitza; Janice Cormier; Wen-Jen Hwu; Hussein A Tawbi; Sapna P Patel; Jeffrey E Lee; Jeffrey E Gershenwald; Christine N Spencer; Vancheswaran Gopalakrishnan; Roland Bassett; Lauren Simpson; Rosalind Mouton; Courtney W Hudgens; Li Zhao; Haifeng Zhu; Zachary A Cooper; Khalida Wani; Alexander Lazar; Patrick Hwu; Adi Diab; Michael K Wong; Jennifer L McQuade; Richard Royal; Anthony Lucci; Elizabeth M Burton; Sangeetha Reddy; Padmanee Sharma; James Allison; Phillip A Futreal; Scott E Woodman; Michael A Davies; Jennifer A Wargo Journal: Lancet Oncol Date: 2018-01-18 Impact factor: 41.316
Authors: Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood Journal: PLoS One Date: 2014-02-03 Impact factor: 3.240
Authors: Anna M Czarnecka; Krzysztof Ostaszewski; Aneta Borkowska; Anna Szumera-Ciećkiewicz; Katarzyna Kozak; Tomasz Świtaj; Paweł Rogala; Iwona Kalinowska; Hanna Koseła-Paterczyk; Konrad Zaborowski; Paweł Teterycz; Andrzej Tysarowski; Donata Makuła; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-12-27 Impact factor: 6.639